Senores Pharmaceuticals Limited Stock Price Today (NSE: SENORES)
Fundamental Score
Senores Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Senores Pharmaceuticals Limited share price today is ₹1376.90, down 2.77% on NSE/BSE as of 16 September 2026. Senores Pharmaceuticals Limited (SENORES) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.34K (Cr). The 52-week high for SENORES share price is ₹1599.00 and the 52-week low is ₹662.45. At a P/E ratio of 48.48x, SENORES is currently trading above its industry average P/E of 34.89x. 0
Senores Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Senores Pharmaceuticals Limited share price chart: 6.16% return over the past month. 52-week high ₹1599.00, 52-week low ₹662.45.
Senores Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1424.20 | ₹1425.00 | ₹1355.60 | ₹1376.90 | 2.23L (Cr) | |
| ₹1470.00 | ₹1475.60 | ₹1400.00 | ₹1416.10 | 1.62L (Cr) | |
| ₹1452.00 | ₹1480.00 | ₹1437.10 | ₹1467.30 | 1.35L (Cr) | |
| ₹1489.80 | ₹1495.00 | ₹1460.00 | ₹1463.10 | 91.24K (Cr) | |
| ₹1519.90 | ₹1525.00 | ₹1460.20 | ₹1488.60 | 2.33L (Cr) | |
| ₹1504.00 | ₹1532.00 | ₹1486.00 | ₹1509.80 | 3.74L (Cr) | |
| ₹1428.40 | ₹1512.00 | ₹1410.40 | ₹1497.50 | 4.04L (Cr) | |
| ₹1442.80 | ₹1465.90 | ₹1420.00 | ₹1428.40 | 1.24L (Cr) | |
| ₹1450.00 | ₹1462.40 | ₹1424.00 | ₹1430.40 | 1.12L (Cr) | |
| ₹1454.70 | ₹1478.80 | ₹1440.20 | ₹1449.50 | 1.70L (Cr) |
Senores Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1442.30 | ₹1532.00 | ₹1355.60 | ₹1376.90 | -4.53% | |
| ₹1326.60 | ₹1599.00 | ₹1306.10 | ₹1432.80 | +8.01% | |
| ₹1343.40 | ₹1509.80 | ₹1287.90 | ₹1305.70 | -2.81% | |
| ₹1042.30 | ₹1360.00 | ₹1001.00 | ₹1329.90 | +27.59% | |
| ₹904.00 | ₹1194.40 | ₹877.55 | ₹1120.65 | +23.97% | |
| ₹797.00 | ₹947.70 | ₹741.90 | ₹899.20 | +12.82% | |
| ₹747.00 | ₹801.40 | ₹706.00 | ₹759.60 | +1.69% | |
| ₹786.00 | ₹849.40 | ₹760.00 | ₹764.90 | -2.68% | |
| ₹825.00 | ₹876.50 | ₹752.40 | ₹787.95 | -4.49% | |
| ₹825.00 | ₹849.10 | ₹738.10 | ₹822.20 | -0.34% | |
| ₹771.20 | ₹832.00 | ₹755.00 | ₹823.70 | +6.81% | |
| ₹689.95 | ₹790.00 | ₹684.60 | ₹771.20 | +11.78% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Senores Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Senores Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SENORES across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Excellent ROCE Performance (17.00%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (26.41%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (55.68%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (30.60%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (7.36x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.00)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Risk Factors
5 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 48.48x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (8.07x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Negative Free Cash Flow (₹-528.53 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Senores Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Senores Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Senores Pharmaceuticals LimitedSenores Pharmac...Selected✓ SENORES • 544319 | 44.7/100 | ₹1376.90₹1377 | ₹6340.62₹6340.62 | 48.48Average 48.5 Average | 0.00%Poor 0.00% Poor | 17.00%Good 17.00% Good | 0.35Excellent 0.4 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9425.50₹9426 | ₹249775.75₹249775.75 | 85.52Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4927.00₹4927 | ₹166759.24₹166759.24 | 78.71Average 78.7 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.00₹1370 | ₹110675.45₹110675.45 | 32.82Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1925.50₹1926 | ₹104025.14₹104025.14 | 95.04Average 95.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.20₹1675 | ₹96391.01₹96391.01 | 26.17Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2099.90₹2100 | ₹96017.92₹96017.92 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.40₹1141 | ₹95306.90₹95306.90 | 29.50Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2289.10₹2289 | ₹94539.83₹94539.83 | 46.25Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price249775.75 Cr
- Torrent Pharmaceuticals Limited share price166759.24 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110675.45 Cr
Senores Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for SENORES — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹16.12 | ₹822.20 | 51x |
| FY 2024 | ₹6.83 | ₹568.60 | 83.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Senores Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for SENORES — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
30.60%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
55.68%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Senores Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SENORES — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Senores Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Senores Pharmaceuticals Limited (SENORES) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Senores Pharmaceuticals Limited
About SENORES (Senores Pharmaceuticals Limited)
Senores Pharmaceuticals Ltd is a global pharmaceutical company dedicated to advancing healthcare through the discovery, development, and commercialization of innovative therapies. ...With a strong emphasis on research and development, Senores Pharmaceuticals is committed to addressing unmet medical needs across a broad range of therapeutic areas. The company's mission is to improve patient outcomes and enhance the quality of life for individuals worldwide by providing access to safe, effective, and affordable medicines. Senores Pharmaceuticals operates with the highest ethical standards and a focus on sustainability, ensuring that its business practices are environmentally responsible and socially conscious. They strive to be a trusted partner for healthcare professionals and patients, offering comprehensive support and resources to optimize treatment outcomes. Driven by a passion for scientific excellence, Senores Pharmaceuticals invests heavily in cutting-edge technologies and strategic collaborations to accelerate the development of novel therapeutics. The company's robust pipeline includes a diverse portfolio of products in various stages of development, targeting diseases with significant unmet needs. Senores Pharmaceuticals is committed to bringing innovative solutions to market that transform the lives of patients. Their experienced team of scientists, clinicians, and business professionals work collaboratively to navigate the complex regulatory landscape and ensure the timely delivery of high-quality products to patients in need. Senores Pharmaceuticals is dedicated to fostering a culture of innovation, collaboration, and patient-centricity, where every employee is empowered to make a difference in the world. Senores Pharmaceuticals is focused on expanding its global reach and strengthening its presence in key markets. The company's commercial operations are supported by a dedicated sales and marketing team that is committed to providing healthcare professionals with the information and resources they need to make informed treatment decisions. Senores Pharmaceuticals has established a strong distribution network to ensure that its products are readily available to patients around the world. In addition to its own product portfolio, Senores Pharmaceuticals is actively seeking partnerships and licensing agreements to expand its offerings and address a wider range of medical needs. The company is dedicated to building long-term relationships with healthcare providers, payers, and patient advocacy groups to improve access to care and promote positive health outcomes.
Company Details
Key Leadership
SENORES Share Price: Frequently Asked Questions
What is the current share price of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited (SENORES) trades at ₹1376.90 on NSE and BSE. Market cap ₹6.34K (Cr). Educational data only.
What is the P/E ratio of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited has a P/E of 48.48x vs industry average 34.89x.
What is the Bull Run score for Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited has a Bull Run score of 44.7/100 based on 25+ financial parameters.
Does Senores Pharmaceuticals Limited pay dividends?
Senores Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited has debt-to-equity of 0.35.
Is Senores Pharmaceuticals Limited a good investment?
Bull Run gives Senores Pharmaceuticals Limited a score of 44.7/100. This is not investment advice — consult a SEBI-registered advisor.